These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1311 related articles for article (PubMed ID: 26325605)

  • 1. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
    Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
    Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival.
    Kim SS; Rait A; Kim E; Pirollo KF; Nishida M; Farkas N; Dagata JA; Chang EH
    ACS Nano; 2014 Jun; 8(6):5494-514. PubMed ID: 24811110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.
    Kim SS; Harford JB; Moghe M; Rait A; Pirollo KF; Chang EH
    Nucleic Acids Res; 2018 Feb; 46(3):1424-1440. PubMed ID: 29202181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual-targeting immunoliposomes using angiopep-2 and CD133 antibody for glioblastoma stem cells.
    Kim JS; Shin DH; Kim JS
    J Control Release; 2018 Jan; 269():245-257. PubMed ID: 29162480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme.
    Kim SS; Rait A; Kim E; Pirollo KF; Chang EH
    Nanomedicine; 2015 Feb; 11(2):301-11. PubMed ID: 25240597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
    Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
    Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
    Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
    Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: in vivo evaluation.
    Danhier F; Messaoudi K; Lemaire L; Benoit JP; Lagarce F
    Int J Pharm; 2015 Mar; 481(1-2):154-61. PubMed ID: 25644286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems.
    Toren A; Pismenyuk T; Yalon M; Freedman S; Simon AJ; Fisher T; Moshe I; Reichardt JK; Constantini S; Mardor Y; Last D; Guez D; Daniels D; Assoulin M; Mehrian-Shai R
    Oncotarget; 2016 Nov; 7(46):74860-74871. PubMed ID: 27556862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temozolomide nanoparticles for targeted glioblastoma therapy.
    Fang C; Wang K; Stephen ZR; Mu Q; Kievit FM; Chiu DT; Press OW; Zhang M
    ACS Appl Mater Interfaces; 2015 Apr; 7(12):6674-82. PubMed ID: 25751368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
    Verreault M; Wehbe M; Strutt D; Masin D; Anantha M; Walker D; Chu F; Backstrom I; Kalra J; Waterhouse D; Yapp DT; Bally MB
    J Control Release; 2015 Dec; 220(Pt A):348-357. PubMed ID: 26528901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Connexin 43 Inhibition Sensitizes Chemoresistant Glioblastoma Cells to Temozolomide.
    Murphy SF; Varghese RT; Lamouille S; Guo S; Pridham KJ; Kanabur P; Osimani AM; Sharma S; Jourdan J; Rodgers CM; Simonds GR; Gourdie RG; Sheng Z
    Cancer Res; 2016 Jan; 76(1):139-49. PubMed ID: 26542214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
    Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P
    J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide.
    Ferrer-Font L; Arias-Ramos N; Lope-Piedrafita S; Julià-Sapé M; Pumarola M; Arús C; Candiota AP
    NMR Biomed; 2017 Sep; 30(9):. PubMed ID: 28570014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A combined preclinical therapy of cannabinoids and temozolomide against glioma.
    Torres S; Lorente M; Rodríguez-Fornés F; Hernández-Tiedra S; Salazar M; García-Taboada E; Barcia J; Guzmán M; Velasco G
    Mol Cancer Ther; 2011 Jan; 10(1):90-103. PubMed ID: 21220494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Encapsulation of Temozolomide in a Calixarene Nanocapsule Improves Its Stability and Enhances Its Therapeutic Efficacy against Glioblastoma.
    Renziehausen A; Tsiailanis AD; Perryman R; Stylos EK; Chatzigiannis C; O'Neill K; Crook T; Tzakos AG; Syed N
    Mol Cancer Ther; 2019 Sep; 18(9):1497-1505. PubMed ID: 31213505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin treatment reduces temozolomide resistance of glioblastoma cells.
    Yang SH; Li S; Lu G; Xue H; Kim DH; Zhu JJ; Liu Y
    Oncotarget; 2016 Nov; 7(48):78787-78803. PubMed ID: 27791206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the STAT3 inhibitor STX-0119 on the proliferation of a temozolomide-resistant glioblastoma cell line.
    Ashizawa T; Akiyama Y; Miyata H; Iizuka A; Komiyama M; Kume A; Omiya M; Sugino T; Asai A; Hayashi N; Mitsuya K; Nakasu Y; Yamaguchi K
    Int J Oncol; 2014 Jul; 45(1):411-8. PubMed ID: 24820265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 66.